Loading company…
Prolium Bioscience develops therapies for severe autoimmune diseases, including its PRO-203 T-cell engager.
Prolium Bioscience is developing PRO-203, a CD20xCD3 T-cell engager for severe autoimmune diseases. It works with healthcare providers and research institutions. Founded in 2025 and based in New York, the company raised USD 50 mn in Series A funding led by RTW Investments on March 3, 2026, to support clinical studies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in